These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29857523)

  • 81. Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need.
    Peña ID; Borlongan C; Shen G; Davis W
    J Stroke; 2017 Jan; 19(1):50-60. PubMed ID: 28178410
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Low Doses of G-CSF Prevent Cerebral Infarction and Maintain Muscle Strength in an Experimental Model of Global Ischemic Stroke.
    da Ros Peruch B; Monteiro BL; Aires R; E Silva CM; Guimaraes MCC; Vasquez EC; Nogueira BV
    Curr Pharm Biotechnol; 2018; 19(6):514-519. PubMed ID: 30019642
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [VEGF-A therapeutic target against hemorrhagic transformation after t-PA treatment].
    Kanazawa M; Takahashi T; Kawamura K; Shimohata T
    Rinsho Shinkeigaku; 2019 Nov; 59(11):699-706. PubMed ID: 31656268
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
    Rahmani MR; Shamsizadeh A; Hakimizadeh E; Allahtavakoli M
    Inflammation; 2018 Dec; 41(6):2052-2059. PubMed ID: 30047001
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke.
    Ishrat T; Fouda AY; Pillai B; Eldahshan W; Ahmed H; Waller JL; Ergul A; Fagan SC
    J Cereb Blood Flow Metab; 2019 Aug; 39(8):1635-1647. PubMed ID: 29537907
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
    Boese AC; Eckert A; Hamblin MH; Lee JP
    Exp Neurol; 2020 Jul; 329():113275. PubMed ID: 32147438
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator.
    Knecht T; Borlongan C; Dela Peña I
    Brain Circ; 2018; 4(3):99-108. PubMed ID: 30450415
    [TBL] [Abstract][Full Text] [Related]  

  • 88. An extended window of opportunity for G-CSF treatment in cerebral ischemia.
    Schneider A; Wysocki R; Pitzer C; Krüger C; Laage R; Schwab S; Bach A; Schäbitz WR
    BMC Biol; 2006 Oct; 4():36. PubMed ID: 17049076
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Repairing the Brain by SCF+G-CSF Treatment at 6 Months Postexperimental Stroke: Mechanistic Determination of the Causal Link Between Neurovascular Regeneration and Motor Functional Recovery.
    Cui L; Wang D; McGillis S; Kyle M; Zhao LR
    ASN Neuro; 2016 Jun; 8(4):. PubMed ID: 27511907
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model.
    Campos F; Qin T; Castillo J; Seo JH; Arai K; Lo EH; Waeber C
    Stroke; 2013 Feb; 44(2):505-11. PubMed ID: 23287783
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
    Sun YY; Morozov YM; Yang D; Li Y; Dunn RS; Rakic P; Chan PH; Abe K; Lindquist DM; Kuan CY
    PLoS One; 2014; 9(6):e98807. PubMed ID: 24911517
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A multitrait genetic study of hemostatic factors and hemorrhagic transformation after stroke treatment.
    Gallego-Fabrega C; Temprano-Sagrera G; Cárcel-Márquez J; Muiño E; Cullell N; Lledós M; Llucià-Carol L; Martin-Campos JM; Sobrino T; Castillo J; Millán M; Muñoz-Narbona L; López-Cancio E; Ribó M; Alvarez-Sabin J; Jiménez-Conde J; Roquer J; Tur S; Obach V; Arenillas JF; Segura T; Serrano-Heras G; Marti-Fabregas J; Freijo-Guerrero M; Moniche F; Castellanos MDM; Morrison AC; Smith NL; de Vries PS; Fernández-Cadenas I; Sabater-Lleal M; ;
    J Thromb Haemost; 2024 Apr; 22(4):936-950. PubMed ID: 38103737
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Infiltration of tissue plasminogen activator through cerebral vessels: evaluation using a rat thromboembolic stroke model.
    Kano T; Harada T; Katayama Y
    Acta Neurochir Suppl; 2003; 86():167-8. PubMed ID: 14753427
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Granulocyte-colony stimulating factor in experimental stroke and its effects on infarct size and functional outcome: A systematic review.
    England TJ; Gibson CL; Bath PM
    Brain Res Rev; 2009 Dec; 62(1):71-82. PubMed ID: 19751764
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats.
    Wang X; Xu L; Wang H; Grzanna R; Zhan Y; Knabb RM; Luettgen JM; Bozarth TA; Galemmo RA; Wong PC; Bernard R; Vargas H; Chopp M; Friedman SM; Feuerstein GZ
    Stroke; 2003 Feb; 34(2):468-74. PubMed ID: 12574562
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.
    Ye Y; Zhang FT; Wang XY; Tong HX; Zhu YT
    J Am Heart Assoc; 2020 Dec; 9(24):e017876. PubMed ID: 33283576
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Blood-brain barrier permeability and tPA-mediated neurotoxicity.
    Abu Fanne R; Nassar T; Yarovoi S; Rayan A; Lamensdorf I; Karakoveski M; Vadim P; Jammal M; Cines DB; Higazi AA
    Neuropharmacology; 2010 Jun; 58(7):972-80. PubMed ID: 20060006
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment.
    Kanazawa M; Igarashi H; Kawamura K; Takahashi T; Kakita A; Takahashi H; Nakada T; Nishizawa M; Shimohata T
    J Cereb Blood Flow Metab; 2011 Jun; 31(6):1461-74. PubMed ID: 21304556
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Improving stroke outcomes in hyperglycemic mice by modulating tPA/NMDAR signaling to reduce inflammation and hemorrhages.
    Lebrun F; Levard D; Lemarchand E; Yetim M; Furon J; Potzeha F; Marie P; Lesept F; Blanc M; Haelewyn B; Rubio M; Letourneur A; Violle N; Orset C; Vivien D
    Blood Adv; 2024 Mar; 8(5):1330-1344. PubMed ID: 38190586
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke.
    Kuo PC; Weng WT; Scofield BA; Furnas D; Paraiso HC; Intriago AJ; Bosi KD; Yu IC; Yen JH
    Blood Adv; 2020 Sep; 4(18):4366-4381. PubMed ID: 32926126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.